Victoria E. Banuchi

Victoria E. Banuchi

Auto-generated profile, based on publicly available information

Victoria E. Banuchi

Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center , Houston, TX 77030

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2013 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LMLuc G T Morris
Luc G T Morris
AKAndrew M Kaufman
Andrew M Kaufman
YGYongxing Gong
Yongxing Gong
DRDeepa Ramaswami
Deepa Ramaswami
LWLogan A Walsh
Logan A Walsh
TCTimothy A. Chan
Timothy A. Chan
Tim Chan and colleagues report the identification of recurrent somatic mutations in FAT1 in glioblastoma, colon cancer and head and neck cancer and show that inactivation of FAT1 promotes Wnt signaling and tumorigenesis. Aberrant Wnt signaling can drive cancer development. In many cancer types, the genetic basis of Wnt pathway activation remains incompletely understood. Here, we report recurrent somatic mutations of the Drosophila melanogaster tumor suppressor–related gene FAT1 in glioblastoma (20.5%), colorectal cancer (7.7%), and head and neck cancer (6.7%). FAT1 encodes a cadherin-like protein, which we found is able to potently suppress cancer cell growth in vitro and in vivo by binding β-catenin and antagonizing its nuclear localization. Inactivation of FAT1 via mutation therefore promotes Wnt signaling and tumorigenesis and affects patient survival. Taken together, these data strongly point to FAT1 as a tumor suppressor gene driving loss of chromosome 4q35, a prevalent region of deletion in cancer. Loss of FAT1 function is a frequent event during oncogenesis. These findings address two outstanding issues in cancer biology: the basis of Wnt activation in non-colorectal tumors and the identity of a 4q35 tumor suppressor.

15 November 2004 in Development
Verified
Journal Article
Open access
PDF file
TSTomomi Shimogori
Tomomi Shimogori
VBVictoria Banuchi
Victoria Banuchi
HNHanyann Y. Ng
Hanyann Y. Ng
JSJonathan B. Strauss
Jonathan B. Strauss
EGElizabeth A. Grove
Elizabeth A. Grove
Recent findings implicate embryonic signaling centers in patterning the mammalian cerebral cortex. We used mouse in utero electroporation and mutant analysis to test whether cortical signaling sources interact to regulate one another. We identified interactions between the cortical hem, rich in Wingless-Int (WNT) proteins and bone morphogenetic proteins (BMPs), and an anterior telencephalic source of fibroblast growth factors (FGFs).Expanding the FGF8 domain suppressed Wnt2b, Wnt3a and Wnt5a expression in the hem. Next to the hem, the hippocampus was shrunken, consistent with its dependence for growth on a hem-derived WNT signal. Maintenance of hem WNT signaling and hippocampal development thus require a constraint on the FGF8 source, which is likely to be supplied by BMP activity. When endogenous BMP signaling is inhibited by noggin, robust Fgf8 expression appears ectopically in the cortical primordium.Abnormal signaling centers were further investigated in mice lacking the transcription factor EMX2, in which FGF8 activity is increased, WNT expression reduced, and the hippocampus defective. Suggesting that these defects are causally related, sequestering FGF8 in Emx2 homozygous mutants substantially recovered WNT expression in the hem and partially rescued hippocampal development.Because noggin can induce Fgf8 expression, we examined noggin and BMP signaling in the Emx2 mutant. As the telencephalic vesicle closed, Nog expression was expanded and BMP activity reduced,potentially leading to FGF8 upregulation. Our findings point to a cross-regulation of BMP, FGF, and WNT signaling in the early telencephalon,integrated by EMX2, and required for normal cortical development.

7 November 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
LMLuc G. T. Morris
Luc G. T. Morris
BTBarry S. Taylor
Barry S. Taylor
TBTrever G. Bivona
Trever G. Bivona
YGYongxing Gong
Yongxing Gong
SEStephanie Eng
Stephanie Eng
TCTimothy A. Chan
Timothy A. Chan
Activation of the PI3K and epidermal growth factor receptor (EGFR) pathway is able to drive oncogenesis in multiple human cancers, including head and neck squamous cell carcinoma. Targeted agents such as cetuximab and erlotinib are currently used in patients with head and neck squamous cell carcinoma, but, in this disease, the genomic alterations that cause pathway activation and determine response to pharmacologic inhibition remain ill-defined. Here, we present a detailed dissection of the EGFR/PI3K pathway, composed of sequencing of the core pathway components, and high-resolution genomic copy number assessment. Mutations were found in PIK3CA (6%), but no point mutations were observed in other pathway genes such as PTEN and EGFR . In contrast, we observed frequent copy number alterations of genes in the pathway, including PIK3CA , EGFR , protein tyrosine phosphatase receptor S ( PTPRS ), and RICTOR . In total, activating genetic pathway alterations were identified in 74% of head and neck tumors. Importantly, intragenic microdeletions of the EGFR phosphatase PTPRS were frequent (26%), identifying this gene as a target of 19p13 loss. PTPRS loss promoted EGFR/PI3K pathway activation, modulated resistance to EGFR inhibition, and strongly determined survival in lung cancer patients with activating EGFR mutations. These findings have important implications for our understanding of head and neck cancer tumorigenesis and for the use of targeted agents for this malignancy.

10 February 2016 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
VBVictoria E. Banuchi
Victoria E. Banuchi
LDLaura Dooley
Laura Dooley
NLNancy Y. Lee
Nancy Y. Lee
DPDavid G. Pfister
David G. Pfister
SMSean McBride
Sean McBride
LMLuc Morris
Luc Morris

18 October 2010 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
SRScott Rickert
Scott Rickert
VBVictoria E. Banuchi
Victoria E. Banuchi
JGJoan D. Germana
Joan D. Germana
MSMichael G. Stewart
Michael G. Stewart
MAMax M. April
Max M. April
Cystic fibrosis (CF) is caused by a mutation in the CF transmembrane conductance regulator gene on the long arm of chromosome 7. This defect alters the transmembrane passage of the chloride ion across cell membranes, resulting in multisystemic dysfunction that can lead to chronic respiratory tract infections, pancreatic insufficiency, and malnutrition.1 Nasal obstruction and chronic rhinosinusitis are otolaryngologic manifestations of the disease.2 Altered viscoelastic properties of mucus that result in bacterial colonization, particularly of Pseudomonas aeruginosa, are thought to contribute to the impaired ciliary clearance seen in patients with CF.2 This ciliary clearance dysfunction can result in obstruction of the sinus ostia, leading to chronic sinusitis and mucosal edema, leading to sinonasal polyposis and nasal obstruction. However, not all patients with CF develop nasal polyposis.

1 July 2015 in Surgical Oncology Clinics of North America
Verified
Journal Article
Closed access
VBVictoria Banuchi
Victoria Banuchi
JMJonathan Mallen
Jonathan Mallen
DKDennis Kraus
Dennis Kraus